LIDDS Interim report January – December 2020
JANUARY – DECEMBER 2020 Net sales amounted to MSEK 0.3 (0.0) Operating expenses amounted to…
Year: 2021
LIDDS and Pharmidea signs manufacturing agreement
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a collaboration agreement has been signed…
Verona Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
Positive Phase 2 results with pMDI ensifentrine in COPD Enrollment ongoing in ENHANCE Phase 3…
Roche announces results from Evrysdi (risdiplam) study in infants with Type 1 spinal muscular atrophy (SMA) published in New England Journal of Medicine
FIREFISH Part 1 data show treatment with Evrysdi at 12 months helped 90% of these…
Valneva Reports FY 2020 Results and Major Corporate Achievements
Excellent progress on clinical programs Unprecedented partnering deal signed with Pfizer for Lyme disease vaccine…
argenx to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021
February 25, 2021Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company…
Antares Pharma to Present at Two Upcoming Investor Conferences
EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”),…
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Initiation of Mechanistic Study of TTP399 expected during Q1 2021 Announcement of First-Patient First-Visit in…
ERYTECH to Participate in Upcoming Virtual Investor Conferences in March
ERYTECH to Participate in Upcoming Virtual Investor Conferences in March Lyon (France) and Cambridge, MA…
Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy
– Data demonstrate that ImmTOR has the potential to enhance transgene expression in the liver…
CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-Broad advancement of clinical pipeline- -Three-arm Phase 2 study of praluzatamab ravtansine (CX-2009) launched in…
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event
Acquires Tetramer Shop; Reveals Details on Upcoming Products PLEASANTON, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE)…
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
Achieved Oxbryta® (voxelotor) net revenues of $41.3 million in the fourth quarter and $123.8 million for…
Alimera Sciences Reports Fourth Quarter and 2020 Results
Fourth Quarter Highlights: Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of…
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results
SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
Seer to Present at the Cowen 41st Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) — Seer, Inc., (Nasdaq: SEER), a life…
Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference
JERSEY, Channel Islands, Feb. 24, 2021 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics…
G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
– G1’s COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the…
Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
— NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a…
InflaRx Announces Proposed Offering of Common Shares and One-Year Warrants
JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…